Arcadia Investment Management Corp MI Makes New Investment in Medpace Holdings, Inc. (NASDAQ:MEDP)

Arcadia Investment Management Corp MI purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 216 shares of the company’s stock, valued at approximately $72,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. State Street Corp increased its holdings in shares of Medpace by 7.2% during the 3rd quarter. State Street Corp now owns 752,957 shares of the company’s stock worth $251,337,000 after buying an additional 50,312 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Medpace by 7.6% during the 3rd quarter. Geode Capital Management LLC now owns 628,054 shares of the company’s stock worth $209,885,000 after purchasing an additional 44,371 shares during the last quarter. Wellington Management Group LLP raised its holdings in Medpace by 36.0% in the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock valued at $138,612,000 after buying an additional 109,886 shares during the period. American Capital Management Inc. lifted its position in Medpace by 2.6% in the third quarter. American Capital Management Inc. now owns 380,646 shares of the company’s stock valued at $127,060,000 after buying an additional 9,592 shares during the last quarter. Finally, FMR LLC boosted its stake in Medpace by 11.8% during the third quarter. FMR LLC now owns 231,019 shares of the company’s stock worth $77,114,000 after buying an additional 24,362 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Down 1.2 %

Medpace stock opened at $340.78 on Friday. Medpace Holdings, Inc. has a 52-week low of $302.01 and a 52-week high of $459.77. The firm has a market cap of $10.38 billion, a PE ratio of 26.98, a price-to-earnings-growth ratio of 3.80 and a beta of 1.36. The company’s 50 day moving average is $343.23 and its two-hundred day moving average is $347.46.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Robert W. Baird upped their price objective on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $381.44.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.